We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

A decade of studies from labs around the world provide a growing evidence base that increasing the power of the brain's gamma rhythms could help fight Alzheimer's, and perhaps other, neurological ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

A decade after scientists at The Picower Institute for Learning and Memory at MIT first began testing whether sensory ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's ...

A new generation of therapeutics looks beyond simply reengineering the gut microbiome to exploiting multiple pathways for novel microbiome and microbial applications.

AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported 2024 results in a February press release ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...